Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients

被引：86

作者：

Illa, Isabel ^{[1
]}

Diaz-Manera, Jordi ^{[1
]}

Rojas-Garcia, Ricard ^{[1
]}

Pradas, Jesus ^{[1
]}

Rey, Antonio ^{[4
]}

Blesa, Rafael ^{[1
]}

Juarez, Candido ^{[3
]}

Gallardo, Eduard ^{[2
]}

机构：

[1] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Neuromuscular Unit, Dept Neurol, E-08193 Barcelona, Spain

[2] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Lab Expt Neurol, E-08193 Barcelona, Spain

[3] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Dept Immunol, E-08193 Barcelona, Spain

[4] Hosp Terrassa, Med Interna Serv, Unitat Neurol, Barcelona, Spain

来源：

JOURNAL OF NEUROIMMUNOLOGY | 2008年 / 201卷

关键词：

Myasthenia Gravis treatment; MuSK antibodies; AChR antibodies; Rituximab;

D O I：

10.1016/j.jneuroim.2008.04.039

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We report the results of treatment with Rituximab in six severe, non-responder MG patients. We treated three AChR+MG and three MuSK+MG patients, representing 2% and 20% of the respective groups of our series. Patients were assessed according to the Myasthenia Gravis Foundation of America (MGFA) recommendations. Antibody titers to AChR and MUSK, lg levels, and IgG Subclasses, were tested before treatment and during a follow-up of 9-22 months. All patients, one class V and five class IVB, improved dramatically, with no side effects. Antibody titers declined in all patients (p=0.006). The decline was significantly better in MuSK + MG patients at 9 months (p=0.046) and correlated with a more Sustained clinical improvement. We did not find any significant changes in IgG4 that could explain the different outcome observed between these two groups. (C) 2008 Elsevier B.V. All rights reserved.

引用

页码：90 / 94

页数：5

共 40 条

[1]

[Anonymous], COCHRANE DATABASE SY

[2]

[Anonymous], 2005, COCHRANE LIB

[3]

[Anonymous], 2007, COCHRANE DATABASE SY

[4] Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis [J].

Baek, William S. ;

Bashey, Asad ;

Sheean, Geoffrey L. .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2007, 78 (07) :771-771

[5] Anti-MuSK antibodies: Correlation with myasthenia gravis severity [J].

Bartoccioni, E. ;

Scuderi, F. ;

Minicuci, G. M. ;

Marino, M. ;

Ciaraffa, F. ;

Evoli, A. .

NEUROLOGY, 2006, 67 (03) :505-507

[6] Progressive multifocal leukoencephalopathy [J].

Berger, Joseph R. .

CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2007, 7 (06) :461-469

[7] Autoimmune channelopathies [J].

Buckley, C ;

Vincent, A .

NATURE CLINICAL PRACTICE NEUROLOGY, 2005, 1 (01) :22-33

[8] Anti-B cell therapy (Rituximab) in the treatment of autoimmune diseases [J].

Chambers, SA ;

Isenberg, D .

LUPUS, 2005, 14 (03) :210-214

[9] Myasthenia gravis: past, present, and future [J].

Conti-Fine, Bianca M. ;

Milani, Monica ;

Kaminski, Henry J. .

JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (11) :2843-2854

[10] Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis [J].

Deymeer, F. ;

Gungor-Tuncer, O. ;

Yilmaz, V. ;

Parman, Y. ;

Serdaroglu, P. ;

Ozdemir, C. ;

Vincent, A. ;

Saruhan-Direskeneli, G. .

NEUROLOGY, 2007, 68 (08) :609-611

← 1 2 3 4 →